Annual General Meeting of May 16, 2018

  • Approval of all ordinary resolutions
  • Renewal of the terms of office of Mr. Thomas Hofstaetter
  • Notice of a new Extraordinary General Meeting on June 19, 2018 

Paris (France), May 16, 2018 – 05:45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company specializing in the development of innovative drugs in oncology, notably against rare or resistant forms of cancer, announces that today’s Ordinary Shareholders’ General Meeting approved all the resolutions submitted to their vote, with over 88% of favorable votes.

In particular, the Ordinary General Meeting renewed the terms of office of Mr. Thomas Hofstaetter as director. Mr. Hofstaetter is Chair of the Onxeo’s Compensation and Business Development Committees.

The quorum of 20.07% did not permit the resolutions to be discussed on an extraordinary basis. The Company’s shareholders are thus invited to attend an Extraordinary General Meeting on the second notice which will be held on June 19, 2018 at 2 pm (CEST) at the Company’s headquarters (49, boulevard du Général Martial Valin, 75015 Paris, France) to deliberate on the same agenda.

The vote of the shareholders who voted by mail for the first general meeting remains valid and counted for the general meeting on the second notice.

 180516_PR_ONXEO_postAG_16mai2018